Illumina, Inc. (NASDAQ:ILMN) Stock Has Average Target Price of $219.69

Shares of Illumina, Inc. (NASDAQ:ILMN) have earned a consensus recommendation of “Hold” from the eighteen research firms that are presently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $222.19.

Several research firms have commented on ILMN. JPMorgan Chase & Co. increased their price target on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Citigroup boosted their target price on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research note on Monday, August 3rd. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Sunday. Argus upped their price objective on shares of Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a report on Thursday, September 3rd. Finally, Piper Sandler upped their price target on shares of Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research note on Monday, September 28th.

Illumina Stock Performance

ILMN stock opened at $278.17 on Wednesday. Illumina has a twelve month low of $88.00 and a twelve month high of $309.35. The business’s fifty day simple moving average is $227.18 and its two-hundred day simple moving average is $181.30. The firm has a market cap of $42.00 billion, a price-to-earnings ratio of 51.90, a PEG ratio of 3.94 and a beta of 1.41. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts predict that Illumina will post 5.36 earnings per share for the current year.

Insiders Place Their Bets

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This represents a 6.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the transaction, the director owned 770,350 shares in the company, valued at $168,244,440. This represents a 13.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 2,061,850 shares of company stock worth $436,479,102 in the last quarter. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Illumina

A number of hedge funds have recently bought and sold shares of ILMN. Fiduciary Financial Advisors acquired a new stake in shares of Illumina during the second quarter valued at $26,000. MCF Advisors LLC grew its holdings in shares of Illumina by 172.4% during the second quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock worth $28,000 after buying an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. purchased a new stake in shares of Illumina during the second quarter worth about $32,000. Rakuten Securities Inc. purchased a new stake in shares of Illumina during the second quarter worth about $33,000. Finally, Elevation Wealth Partners LLC raised its position in shares of Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after buying an additional 84 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.